Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

References

• Metzger Filho O, Saini KS, Azim HAJ Jr., Awada A, on behalf of AROME. Prevention and management of major side effects of targeted agents in breast cancer. [Epub ahead of print] Crit Rev Oncol Hematol 2011; PMID: 20817545
   PubMed Web of Science ®Google Scholar
• Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913 - 21; http://dx.doi.org/10.1158/1078-0432.CCR-06-2610; PMID: 17606725
   PubMed Web of Science ®Google Scholar
• Keefe DM, Gibson RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 2007; 15:483 - 90; http://dx.doi.org/10.1007/s00520-006-0181-z; PMID: 17103195
   PubMed Web of Science ®Google Scholar
• Goss P, Smith I, O'Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F, et al. Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. SABCS 2011 [abstract]
   Google Scholar
• Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006; 7:326 - 31; http://dx.doi.org/10.3816/CLC.2006.n.014; PMID: 16640804
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85 - 94; PMID: 12467226
   PubMed Web of Science ®Google Scholar
• Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006; 18:2089 - 97; http://dx.doi.org/10.1016/j.cellsig.2006.05.015; PMID: 16815674
   PubMed Web of Science ®Google Scholar
• Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13:1114 - 9; http://dx.doi.org/10.1634/theoncologist.2008-0816; PMID: 18849320
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr., Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538 - 46; http://dx.doi.org/10.1200/JCO.2009.23.3734; PMID: 19786658
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9:Suppl 3 10 - 5; http://dx.doi.org/10.1634/theoncologist.9-suppl_3-10; PMID: 15163842
   PubMed Web of Science ®Google Scholar
• Crown JP, Burris HA 3rd, Boyle F, Jones S, Koehler M, Newstat BO, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 112:317 - 25; http://dx.doi.org/10.1007/s10549-007-9860-9; PMID: 18204897
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, et al. First Results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. SABCS 2010 [abstract]
   Google Scholar
• Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008; 5:268 - 78; http://dx.doi.org/10.1038/ncponc1087; PMID: 18349858
   PubMedGoogle Scholar
• McCole DF, Barrett KE. Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function. Acta Physiol (Oxf) 2009; 195:149 - 59; http://dx.doi.org/10.1111/j.1748-1716.2008.01929.x; PMID: 18983445
   PubMed Web of Science ®Google Scholar
• Hare KJ, Hartmann B, Kissow H, Holst JJ, Poulsen SS. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res 2007; 13:5170 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-07-0574; PMID: 17785573
   PubMed Web of Science ®Google Scholar
• Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004; 5:115 - 20; http://dx.doi.org/10.1016/S1535-6108(04)00032-7; PMID: 14998487
   PubMed Web of Science ®Google Scholar
• Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6:1449 - 54; http://dx.doi.org/10.4161/cbt.6.9.4622; PMID: 17881902
   PubMed Web of Science ®Google Scholar
• Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095 - 100; http://dx.doi.org/10.1046/j.1440-1746.2003.03136.x; PMID: 12911669
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O’Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305 - 13; http://dx.doi.org/10.1200/JCO.2005.16.584; PMID: 15955900
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009; 15:6702 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-09-0369; PMID: 19825948
   PubMed Web of Science ®Google Scholar
• Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009; 27:1191 - 6; http://dx.doi.org/10.1200/JCO.2008.18.3285; PMID: 19188677
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30:1426 - 47; http://dx.doi.org/10.1016/j.clinthera.2008.08.008; PMID: 18803986
   PubMed Web of Science ®Google Scholar
• Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006; 14:890 - 900; http://dx.doi.org/10.1007/s00520-006-0040-y; PMID: 16604351
   PubMed Web of Science ®Google Scholar
• Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998; 71:104 - 7; http://dx.doi.org/10.1006/gyno.1998.5158; PMID: 9784328
   PubMed Web of Science ®Google Scholar
• Guchelaar HJ, ten Napel CH, de Vries EG, Mulder NH. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) 1994; 6:40 - 8; http://dx.doi.org/10.1016/S0936-6555(05)80367-X; PMID: 7909688
   PubMedGoogle Scholar
• Zhang C, Xu YG, Duan XN, Liu YH, Zhao JX, Xu L, et al. Role of granulocyte colony-stimulating factor in paclitaxel-induced intestinal barrier breakdown and bacterial translocation in rats. Chin Med J (Engl) 2011; 124:1870 - 5; PMID: 21866617
   PubMed Web of Science ®Google Scholar
• Jamieson SM, Liu JJ, Connor B, Dragunow M, McKeage MJ. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology 2007; 28:1092 - 8; http://dx.doi.org/10.1016/j.neuro.2007.04.009; PMID: 17686523
   PubMed Web of Science ®Google Scholar
• Tatsushima Y, Egashira N, Kawashiri T, Mihara Y, Yano T, Mishima K, et al. Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin. J Pharmacol Exp Ther 2011; 337:226 - 35; http://dx.doi.org/10.1124/jpet.110.175976; PMID: 21233199
   PubMed Web of Science ®Google Scholar
• Chentanez V, Thanomsridejchai N, Duangmardphon N, Agthong S, Kaewsema A, Huanmanop T, et al. Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. J Med Assoc Thai 2009; 92:50 - 7; PMID: 19260244
   PubMedGoogle Scholar
• Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116:464 - 70; http://dx.doi.org/10.1002/ijc.21082; PMID: 15800945
   PubMed Web of Science ®Google Scholar
• Gibson RJ, Stringer AM, Bowen JM, Logan RM, Yeoh AS, Burns J, et al. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 2007; 6:541 - 7; http://dx.doi.org/10.4161/cbt.6.4.3848; PMID: 17457046
   PubMed Web of Science ®Google Scholar
• Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33 - 41; http://dx.doi.org/10.1007/s00280-007-0570-0; PMID: 17703303
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemother Pharmacol 2009; 63:239 - 51; http://dx.doi.org/10.1007/s00280-008-0732-8; PMID: 18351341
   PubMed Web of Science ®Google Scholar